Machine learning active-nematic hydrodynamics

Machine learning active-nematic hydrodynamics

Hydrodynamic theories successfully describe many-body programs out of equilibrium when it comes to just a few macroscopic parameters. However, such parameters are troublesome to find out from microscopic data. Seldom is that this problem extra obvious than in lively matter, the place the hydrodynamic parameters are actually fields that encode the distribution of energy-injecting microscopic parts. Here, we use lively nematics to reveal that neural networks can map out the spatiotemporal variation of a number of hydrodynamic parameters and forecast the chaotic dynamics of those programs.

We analyze biofilament/molecular-motor experiments with microtubule/kinesin and actin/myosin complexes as laptop imaginative and prescient issues. Our algorithms can decide how exercise and elastic moduli change as a operate of area and time, in addition to adenosine triphosphate (ATP) or motor focus. The solely enter wanted is the orientation of the biofilaments and never the coupled velocity subject which is tougher to entry in experiments. We may also forecast the evolution of those chaotic many-body programs solely from picture sequences of their previous utilizing a mixture of autoencoders and recurrent neural networks with residual structure. In life like experimental setups for which the preliminary circumstances will not be completely identified, our physics-inspired machine-learning algorithms can surpass deterministic simulations.

Blending of various biopolymers, e.g., collagen, chitosan, silk fibroin and cross-linking modifications of those mixtures can result in new supplies with improved physico-chemical properties, in comparison with single-component scaffolds. Three-dimensional scaffolds based mostly on three-component mixtures of silk fibroin, collagen and chitosan, chemically cross-linked, have been ready and their physico-chemical and organic properties have been evaluated. A mix of EDC (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) and NHS (N-hydroxysuccinimide) was used as a cross-linking agent. FTIR was used to watch the place of the peaks attribute for collagen, chitosan and silk fibroin. The following properties relying on the scaffold construction have been studied: swelling conduct, liquid uptake, moisture content material, porosity, density, and mechanical parameters.

Scanning Electron Microscopy imaging was carried out. Additionally, the organic properties of those supplies have been assessed, by metabolic exercise assay. The outcomes confirmed that the three-component mixtures, cross-linked by EDC/NHS and ready by lyophilization methodology, offered porous constructions. They have been characterised by a excessive swelling diploma. The composition of scaffolds has an affect on mechanical properties. All of the studied supplies have been cytocompatible with MG-63 osteoblast-like cells. Our research paves the way in which for artificial-intelligence characterization and management of coupled chaotic fields in numerous bodily and organic programs, even within the absence of information of the underlying dynamics.

 Machine learning active-nematic hydrodynamics

Evaluating Whole Blood Clotting in vitro on Biomaterial Surfaces

Biomaterial-associated thrombosis continues to be a significant concern for blood-contacting implants. After the medical system is implanted and is available in contact with blood, a number of advanced reactions happen, which can result in thrombus formation and failure of the system. Therefore, it’s important to guage the biomaterial interplay with the entire blood. Several research have been reported within the literature that consider completely different steps within the coagulation cascade, resembling protein adsorption, plasma activation, and platelet adhesion in vitro, nonetheless, analysis of complete blood clotting on biomaterial surfaces is just not extensively reported.

Here, a protocol to guage complete blood clotting in vitro on 2D biomaterials surfaces by way of a easy and quick hemolysis assay is offered. Whole human blood is positioned onto the biomaterial surfaces and is allowed to clot for various time durations. After the particular time intervals, the surfaces are transferred into deionized (DI) water to launch the free hemoglobin and the absorbance of this answer is measured. The absorbance worth is proportional to the free hemoglobin focus within the DI water as a consequence of lysis of crimson blood cells and offers an oblique correlation to the extent of blood clotting on the biomaterial surfaces. This protocol offers a quick, facile and efficient methodology to measure the anti-thrombogenic properties of biomaterials.

Syrian Hamster IgG Isotype Control

SIGGB-200 200 µg
EUR 472.24

Syrian Hamster IgG Isotype Control

SIGGF-200 200 µg
EUR 545.04

Syrian Hamster IgG Isotype Control

SIGGPE-100 100 µg
EUR 515.92

Syrian Hamster IgG Isotype Control

SIGGPP5.5-100 100 µg
EUR 676.08

Syrian Hamster IgG Isotype Control

SIGGPP5.5-25 25 µg
EUR 355.76

Syrian Hamster IgG Isotype Control

SIGGPU-500 500 µg
EUR 428.56

Armenian Hamster IgG Isotype control

AIGGA-100 100 µg
EUR 574.16

Armenian Hamster IgG Isotype control

AIGGA-25 25 µg
EUR 282.96

Armenian Hamster IgG Isotype control

AIGGB-200 200 µg
EUR 472.24

Armenian Hamster IgG Isotype control

AIGGB-50 50 µg
EUR 239.28

Armenian Hamster IgG Isotype control

AIGGF-200 200 µg
EUR 545.04

Armenian Hamster IgG Isotype control

AIGGF-50 50 µg
EUR 268.4

Armenian Hamster IgG Isotype control

AIGGPE-100 100 µg
EUR 515.92

Armenian Hamster IgG Isotype control

AIGGPE-25 25 µg
EUR 253.84

Armenian Hamster IgG Isotype control

AIGGPP-100 100 µg
EUR 574.16

Armenian Hamster IgG Isotype control

AIGGPP-25 25 µg
EUR 268.4

Armenian Hamster IgG Isotype control

AIGGPP5.5-100 100 µg
EUR 646.96

Armenian Hamster IgG Isotype control

AIGGPP5.5-25 25 µg
EUR 282.96

Armenian Hamster IgG Isotype control

AIGGPU-50 50 µg
EUR 195.6

Armenian Hamster IgG Isotype control

AIGGPU-500 500 µg
EUR 428.56

Hamster IgG, purified (Syrian, isotype control)

20003-1 1 mg
EUR 141

Hamster IgG, purified (Armenian, Isotype control)

20003-1AH 1 mg
EUR 263

Hamster (Arnenian) IgG Isotype Control (FITC)

abx405030-01mg 0.1 mg
EUR 384

Hamster (Arnenian) IgG Isotype Control (RPE)

abx405031-01mg 0.1 mg
EUR 509

Hamster (Syrian) IgG Isotype Control (FITC)

abx405033-01mg 0.1 mg
EUR 398

Hamster IgG-Biotin conjugate, isotype control (Syrian)

20003-1-B 100 test
EUR 164

Hamster IgG-Cy5 conjugate, isotype control (Syrian)

20003-1-Cy5 50 tests
EUR 225

Hamster IgG-FITC conjugate, isotype control (Syrian)

20003-1-F 100 tests
EUR 164

Hamster IgG-HRP conjugate, isotype control (Syrian)

20003-1-HP 100 tests
EUR 164

Hamster IgG-R-PE conjugate, isotype control (Syrian)

20003-1-PE 50 tests
EUR 225

Armenian Hamster IgG Isotype Control (PIP), APC-100ug

QAB69-APC-100ug 100ug
EUR 293

Hamster IgG-R-PE-Cy5.5 conjugate, isotype control (Syrian)

20003-1-PC5 50 tests
EUR 250

Armenian Hamster IgG Isotype Control (PIP), PerCP-Cy5.5-100ug

QAB69-PCP55-100ug 100ug
EUR 326

Rat IgG-Biotin conjugate (isotype control) (Isotype control)

20005-B 100 ug
EUR 164

Rat IgG-FITC conjugate (isotype control) (Isotype control)

20005-F 100 ug
EUR 164

Rat IgG-HRP conjugate (isotype control) (Isotype control)

20005-HP 100 ug
EUR 164

Rat IgG-PE conjugate (isotype control) (Isotype control)

20005-PE 25 tests
EUR 202

Rabbit IgG Isotype Control

abx125003-100ul 100 ul
EUR 203

Rabbit IgG Isotype Control

IC001-100ul 100ul
EUR 122

Mouse IgG Isotype Control

IC002-100ul 100ul
EUR 122

IgG Isotype Control antibody

10R-6524 50 ug
EUR 133
Description: Armenian Hamster monoclonal IgG Isotype Control antibody

IgG Isotype Control antibody

10R-6525 50 ug
EUR 133
Description: Syrian Hamster monoclonal IgG Isotype Control antibody

Rat IgG Isotype Control

31-AR15 10 mg
EUR 220
Description: Purified Rat IgG Isotype Control

Rat IgG purified (isotype control)

20005-1-200 0.5 ml
EUR 103

Rat IgG, purified (Isotype control)

20005-5 5 mg
EUR 286

Sheep IgG, purified (isotype control)

20006-1 1 mg
EUR 141

Rabbit IgG-biotinylated (isotype control)

20009-BT-1 1 mg
EUR 286

Rabbit IgG Isotype control, Concentrate

NG910C 0.5 ml
EUR 392

FITC Rabbit IgG - Isotype control

DB1000 100 tests
EUR 422

FITC Rabbit IgG - Isotype control

DB-1000 100 tests
EUR 422

IgG Isotype Control antibody (FITC)

61R-1136 50 ug
EUR 165
Description: Armenian Hamster monoclonal IgG Isotype Control antibody (FITC)

IgG Isotype Control antibody (PE)

61R-1337 200 ug
EUR 440
Description: Armenian Hamster monoclonal IgG Isotype Control antibody (PE)

IgG Isotype Control antibody (PE)

61R-1338 50 ug
EUR 181
Description: Syrian Hamster monoclonal IgG Isotype Control antibody (PE)

IgG Isotype Control antibody (biotin)

61R-1586 50 ug
EUR 165
Description: Armenian Hamster monoclonal IgG Isotype Control antibody (biotin)

IgG Isotype Control antibody (biotin)

61R-1587 50 ug
EUR 165
Description: Syrian Hamster monoclonal IgG Isotype Control antibody (biotin)

IgG Isotype Control antibody (allophycocyanin)

61R-1768 100 ug
EUR 349
Description: Armenian Hamster monoclonal IgG Isotype Control antibody (allophycocyanin)

IgG Isotype Control antibody (allophycocyanin)

61R-1769 50 ug
EUR 219
Description: Syrian Hamster monoclonal IgG Isotype Control antibody (allophycocyanin)

IgG Isotype Control antibody (FITC)

61R-1800 25 ug
EUR 205
Description: Rabbit polyclonal IgG Isotype Control antibody (FITC)

Donkey IgG (Control, non-immune, isotype control)

20028-1 1 mg
EUR 164

Rabbit IgG Isotype Control APC Conjugate

APCCON 0.15 mg
EUR 261

Rabbit IgG Isotype Control FITC Conjugate

FITCCON 0.15 mg
EUR 261

Mouse IgG Isotype Control PerCP Conjugate

MPERCPCON 0.15 mg
EUR 261

Mouse IgG Isotype Control RPE Conjugate

MRPECON 0.15 mg
EUR 261

Rabbit IgG Isotype Control PerCP Conjugate

PERCPCON 0.15 mg
EUR 261

Rabbit IgG Isotype Control RPE Conjugate

RPECON 0.15 mg
EUR 261

Mouse IgG Isotype Control APC Conjugate

MAPCCON 0.15 mg
EUR 261

Mouse IgG Isotype Control FITC Conjugate

MFITCCON 0.15 mg
EUR 261

Human IgG-HRP Conjugate (isotype control)

20007-1-HP 500 ug
EUR 202

Mouse IgG-Biotin conjugate (isotype control)

20008-B 50 Tests
EUR 164

Mouse IgG-Biotin conjugate (isotype control)

20008-BT-1 1 mg
EUR 164

Mouse IgG-FITC conjugate (isotype control)

20008-F 100 tests
EUR 164

Mouse IgG-HRP conjugate (isotype control)

20008-HP 50 Tests
EUR 164

Mouse IgG-PE conjugate (isotype control)

20008-PE 50 Tests
EUR 164

Rabbit IgG-FITC conjugate (isotype control)

20009-F 100 ug
EUR 164

Rabbit IgG-HRP conjugate (isotype control)

20009-HP 100 ug
EUR 164

Rabbit IgG-PE conjugate (isotype control)

20009-PE 100 tests
EUR 225

Goat IgG-FITC conjugate (isotype control)

20011-F 100 ug
EUR 164

Goat IgG-HRP conjugate (isotype control)

20011-HP 100 ug
EUR 164

Goat IgG-PE conjugate (isotype control)

20011-PE 100 tests
EUR 225

Donkey IgG (non-immune, isotype control) IgG, purified

20015-10 10 mg
EUR 286

Goat IgG (-ve control for flow cytometry) (isotype control)

20011-100 100 test
EUR 103

Llama IgG (Control, non-immune, isotype control, ELISA grade)

20030-1 1 mg
EUR 164

Camel IgG (Control, non-immune, isotype control, ELISA grade)

20031-1 1 mg
EUR 164

Alpaca IgG (Control, non-immune, isotype control, ELISA grade)

20032-1 1 mg
EUR 164

G. Pig IgG-Biotin conjugate (isotype control)

20004-B 100 ug
EUR 202

G. Pig IgG-FITC conjugate (isotype control)

20004-F 100 ug
EUR 202

G. Pig IgG-HRP conjugate (isotype control)

20004-HP 100 ug
EUR 202

Rat IgG Fab fragment, purified (isotype control)

20005-1-FAB 1 mg
EUR 164

Rat IgG (Fc) fragment, purified (isotype control)

20005-1-FC 0.5 mg
EUR 250

Human IgG-Fc fragment purified (isotype control)

20007-F100 100 ug
EUR 141

Human IgG-Fc fragment purified (isotype control)

20007-F1000 1 mg
EUR 347

Mouse IgG Fab-Biotin conjugate (isotype control)

20008-Fab-B 100 ug
EUR 164

Mouse IgG Fab-FITC conjugate (isotype control)

20008-Fab-F 100 ug
EUR 164

Mouse IgG Fab-HRP conjugate (isotype control)

20008-Fab-HP 100 ug
EUR 164

Goat IgG (fc)-Biotin conjugate (isotype control)

20011-Fc-B 100 ug
EUR 164

Goat IgG (fc)-FITC conjugate (isotype control)

20011-Fc-F 100 ug
EUR 164

Goat IgG (fc)-HRP conjugate (isotype control)

20011-Fc-HP 100 ug
EUR 164

Chimpanzee IgG (non-immune, isotype control), purified

20012-Ch-1 1 mg
EUR 225

Donkey IgG (non-immune, isotype control), purified

20015-1 1 mg
EUR 141

Dog IgG (isotype control, non-immune), purified

20016-1 1 mg
EUR 141

Baboon IgG (non-immune, isotype control), purified

20118-1 1 mg
EUR 202

Baboon IgG (non-immune, isotype control), purified

20118-10 10 mg
EUR 895

Bat IgG (non-immune, isotype control), purified

20121-1 25 ug
EUR 286

Goat F(ab')2 IgG Isotype Control

abx405076-05mg 0.5 mg
EUR 411

Mouse IgG Isotype control; Ready-To-Use

NG903 7 ml
EUR 241

IgG Isotype Control Fc fusion protein (FITC)

35R-0013 50 ug
EUR 165
Description: Syrian Hamster monoclonal IgG Isotype Control Fc fusion protein (FITC)

Rabbit Isotype Control

abx200646-100ug 100 ug
EUR 328

Rabbit Isotype Control

IMN-001 100 µg
EUR 199.5

Cat IgG, unlabeled (non-immune, isotype control) purified

20002-1-UL 1 mg
EUR 164

Rat IgG, purified (Whole, non-immune) (isotype control)

20005-1 1 mg
EUR 141

Rat IgG (Fc)-Biotin Conjuagte (isotype control), purified

20005-1-FC-B 0.1 mg
EUR 225

Rat IgG (Fc)-FITC Conjuagte (isotype control), purified

20005-1-FC-F 0.1 mg
EUR 225

Rat IgG (Fc)-HRP Conjuagte (isotype control), purified

20005-1-FC-HP 0.1 mg
EUR 225

Rat IgG, purified (Whole, non-immune) (isotype control)

20005-10 10 mg
EUR 408

Human IgG, purified (serum, non-immune, isotype control)

20007-1-1 1 mg
EUR 141

Human IgG, purified (serum, non-immune, isotype control)

20007-1-100 100 mg
EUR 895

Human IgG, purified (serum, non-immune, isotype control)

20007-1-25 25 mg
EUR 651

Human IgG, purified (serum, non-immune, isotype control)

20007-1-5 5 mg
EUR 286

Mouse IgG, purified (serum non-immune, isotype control)

20008-1 1 mg
EUR 141

Mouse IgG, purified (serum non-immune, isotype control)

20008-100 100 mg
EUR 598

Mouse IgG, purified (serum non-immune, isotype control)

20008-5 5 mg
EUR 286

Mouse IgG F(c)-Biotin conjugate (isotype control)

20008-Fc-B 100 ug
EUR 164

Mouse IgG F(c)-FITC conjugate (isotype control)

20008-Fc-F 100 ug
EUR 164

Mouse IgG F(c)-HRP conjugate (isotype control)

20008-Fc-HP 100 ug
EUR 164

Mouse IgG-R-PE-Cy5 conjugate (isotype control)

20008-PC5 50 Tests
EUR 225

Rabbit IgG, purified (serum non-immune, isotype control)

20009-1 1 mg
EUR 141

Rabbit IgG, purified (serum non-immune, isotype control)

20009-25 25 mg
EUR 469

Rabbit IgG, purified (serum non-immune, isotype control)

20009-5 5 mg
EUR 286

Rabbit IgG F(c)-biotin conjugate, isotype control

20009-Fc-B 100 ug
EUR 164

Rabbit IgG F(c)-FITC conjugate, isotype control

20009-Fc-F 100 ug
EUR 164

Rabbit IgG F(c)-HRP conjugate, isotype control

20009-Fc-HP 100 ug
EUR 164

Chicken IgG unlabeled (isotype control, non-immune), purified

20010-1 1 mg
EUR 141

Goat IgG, purified (serum non-immune, isotype control)

20011-1 1 mg
EUR 141

Goat IgG, purified (serum non-immune, isotype control)

20011-25 25 mg
EUR 469

Goat IgG, purified (serum non-immune, isotype control)

20011-5 5 mg
EUR 286

Monkey IgG (Rhesus, non-immune, isotype control), purified

20012-1 1 mg
EUR 202

Squirrel Monkey IgG (non-immune, isotype control), purified

20012-1-SM 100 ug
EUR 164

Monkey IgG (Rhesus, non-immune, isotype control), purified

20012-10 10 mg
EUR 895

Pig IgG (swine non-immune, isotype control), purified

20017-1 1 mg
EUR 141

Monkey IgG (Cynomolgous, non-immune, isotype control), purified

20018-1 1 mg
EUR 202

Monkey IgG (Cynomolgous, non-immune, isotype control), purified

20018-10 10 mg
EUR 895

Ferret IgG/IgM/IgA, semi-purified (isotype control)

20020-1 1 mg
EUR 225

Turkey IgG, purified (non-immune, isotype control) Serum

20115-1 1 mg
EUR 141

Turkey IgG, purified (non-immune, isotype control) Serum

20115-5 5 mg
EUR 225

Goat F(ab')2 IgG Isotype Control (FITC)

abx405077-100tests 100 tests
EUR 495

Goat F(ab')2 IgG Isotype Control (RPE)

abx405078-05ml 0.5 ml
EUR 537

Ferret IgG (Control, non-immune, isotype control), semi-pure for ELISA

20021-1 100 ug
EUR 225

Elk IgG, semi-pure for ELISA (Control, non-immune, isotype control)

20024-1 100 ug
EUR 225

Deer IgG, semi-pure for ELISA (Control, non-immune, isotype control)

20024-2 100 ug
EUR 225

Bison IgG, semi-pure for ELISA (Control, non-immune, isotype control)

20025-1 100 ug
EUR 225

Raccoon IgG, semi-pure for ELISA (Control, non-immune, isotype control)

20026-1 100 ug
EUR 225

Skunk IgG, semi-pure for ELISA (Control, non-immune, isotype control)

20027-1 100 ug
EUR 225

Positive control tissue section for each antibody; Based on availability INQUIRE

Control-Slides Set of 5
EUR 176

Rat IgG2a Isotype Control

11-168-C025 0.025 mg
EUR 87

Rat IgG2b Isotype Control

11-169-C025 0.025 mg
EUR 87

Mouse IgG1 Isotype Control

abx139002-01mg 0.1 mg
EUR 314

Mouse IgG2a Isotype Control

abx139004-01mg 0.1 mg
EUR 314

Mouse IgG2a Isotype Control

abx139005-01mg 0.1 mg
EUR 314

Mouse IgG2b Isotype Control

abx139006-01mg 0.1 mg
EUR 314

Mouse IgG2b Isotype Control

abx139011-01mg 0.1 mg
EUR 314

Mouse IgG1 Isotype Control

abx139001-01mg 0.1 mg
EUR 314

Mouse IgM Isotype Control

abx139003-01mg 0.1 mg
EUR 314

Mouse IgG1 Isotype Control

abx139008-01mg 0.1 mg
EUR 314

Mouse IgG2a Isotype Control

abx139009-01mg 0.1 mg
EUR 314

Spinal wire damage (SCI) usually ends in long-lasting useful deficits, largely as a consequence of major and secondary white matter injury on the website of damage. The transplantation of neural stem cells (NSCs) has proven promise for re-establishing communications between separated areas of the spinal wire by way of the insertion of latest neurons between the injured axons and goal neurons. However, the inhibitory microenvironment that develops after SCI usually causes endogenous and transplanted NSCs to distinguish into glial cells moderately than neurons. Functional biomaterials have been proven to mitigate the results of the antagonistic SCI microenvironment and promote the neuronal differentiation of NSCs.

A transparent understanding of the mechanisms of neuronal differentiation inside the injury-induced microenvironment would possible permit for the event of remedy methods designed to advertise the innate potential of NSCs to distinguish into neurons. The elevated differentiation of neurons might contribute to relay formation, facilitating useful restoration after SCI. In this assessment, we summarize present methods used to reinforce the neuronal differentiation of NSCs by way of the reconstruction of the SCI microenvironment and to enhance the intrinsic neuronal differentiation skills of NSCs, which is important for SCI restore.


Development of a Biomimetic Hydrogel Based on Predifferentiated Mesenchymal Stem-Cell-Derived ECM for Cartilage Tissue Engineering

Development of a Biomimetic Hydrogel Based on Predifferentiated Mesenchymal Stem-Cell-Derived ECM for Cartilage Tissue Engineering

The use of decellularized extracellular matrix (dECM) as a biomaterial has been an vital step ahead for the event of purposeful tissue constructs. In addition to tissues and organs, cell cultures are gaining a lot of consideration as a substitute supply of dECM. In this work, a novel biomimetic hydrogel is developed primarily based on dECM obtained from mesenchymal stem cells (mdECM) for cartilage tissue engineering. To this finish, cells are seeded underneath particular tradition situations to generate an early chondrogenic extracellular matrix (ECM) offering cues and components essential for cartilage improvement.

The composition is decided by quantitative, histological, and mass spectrometry methods. Moreover, the decellularization course of is evaluated by measuring the DNA content material and compositional analyses, and the hydrogel is formulated at completely different concentrations (3% and 6% w/v). Results present that mdECM derived hydrogels possess glorious biocompatibility and appropriate physicochemical and mechanical properties for their injectability. Furthermore, it’s evidenced that this hydrogel is ready to induce chondrogenesis of mesenchymal stem cells (MSCs) with out supplemental components and, moreover, to kind hyaline cartilage-like tissue after in vivo implantation. These findings exhibit for the primary time the potential of this hydrogel primarily based on mdECM for functions in cartilage restore and regeneration.

Manufacturing macroscale cell-laden architectures is one of the most important challenges confronted these days within the area of tissue engineering. Such dwelling constructs, in reality, pose strict necessities for vitamins and oxygen provide that may hardly be addressed by means of easy diffusion in vitro or with out a purposeful vasculature in vivo. In this context, within the final twenty years, a substantial quantity of work has been carried out to develop sensible supplies that might actively present oxygen-release to distinction native hypoxia in large-size constructs.

This evaluation offers an summary of the at the moment obtainable oxygen-releasing supplies and their synthesis and mechanism of motion, highlighting their capacities underneath in vitro tissue cultures and in vivo contexts. Additionally, we additionally showcase an rising idea, herein termed as “dwelling supplies as releasing techniques”, which depends on the mixture of biomaterials with photosynthetic microorganisms, particularly algae, in an “unconventional” try to produce the broken or re-growing tissue with the required provide of oxygen.

Prionace glauca pores and skin collagen bioengineered constructs as a promising strategy to set off cartilage regeneration

Representing a technique of marine by-products valorization, primarily based on isolation of biocompounds and evaluation of biomedical applicability, the potential of blue shark (Prionace glauca (PG)) pores and skin collagen to induce chondrogenic differentiation of human adipose stem cells (hASC) was investigated, with and with out exogenous stimulation. For that, a cryogelation methodology was utilized to supply extremely interconnected porous three-d (3D) constructs made of collagen and collagen:hyaluronic acid (20:1). In vitro research reveal that hASC adhere abundantly to the constructs which then suggests the early chondrogenic differentiation of these cells.

These findings are supported by the mRNA expression encoding chondrogenic-related markers like Coll II and Sox-9 which can be markedly upregulated at an early stage for each situations, with and with out exogenous stimulation. The introduction of hyaluronic acid (Hya) appears to play a essential function at later time factors, as proven by the evident immunodetection of aggrecan (ACAN), even with out exogenous stimulation. It is hypothesized that the PG collagen itself can help chondrogenic differentiation at early time factors, however exogenous stimulation is required to make sure phenotype upkeep. The current work highlights the relevance of utilizing blue shark collagen biopolymer as a constructing block to supply extremely efficient short-term matrices for cartilage functions.

 Development of a Biomimetic Hydrogel Based on Predifferentiated Mesenchymal Stem-Cell-Derived ECM for Cartilage Tissue Engineering

L-histidine controls the hydroxyapatite mineralization with plate-like morphology: Effect of focus and media

Hydroxyapatite (HA) is the principle inorganic element of bone and dentin, and their non-stoichiometric compositions and plate-shaped morphology is accountable for their bioactivity and osteoconductive nature. Collagenous (CPs) and non-collagenous proteins (NCPs) facilitate mineralization and regulate structural properties of HA by means of their side-chains. The bioactivity of artificial HA doesn’t often match with the HA present in bone and, subsequently, there may be a want to know the function of biomolecules in bone mineralization with the intention to develop non-stoichiometric plate-shaped HA for bone grafts. Role of a number of amino acids has been investigated however the function of L-his has been not often investigated underneath physiological situations although it’s a half of HA inhibitor proteins, like albumin, amelogenin, and histidine-rich proteins.

Rat IgG2b Isotype Control

RIGG2BF-50 50 µg
EUR 151.92

Rat IgG2b Isotype Control

RIGG2BPE-100 100 µg
EUR 268.4

Rat IgG2b Isotype Control

RIGG2BPE-25 25 µg
EUR 151.92

Rat IgG2b Isotype Control

RIGG2BPP-100 100 µg
EUR 574.16

Rat IgG2b Isotype Control

RIGG2BPP-25 25 µg
EUR 268.4

Rat IgG2b Isotype Control

RIGG2BPP5.5-100 100 µg
EUR 515.92

Rat IgG2b Isotype Control

RIGG2BPP5.5-25 25 µg
EUR 282.96

Rat IgG2b Isotype Control

RIGG2BPU-50 50 µg
EUR 122.8

Rat IgG2b Isotype Control

RIGG2BPU-500 500 µg
EUR 370.32

Rat IgG2b Isotype Control

31R-IC001 500 ug
EUR 241
Description: Purified Rat IgG2b Isotype Control

Rat IgG2b unconjugated (isotype control)

20005-13 100 ug
EUR 164

Rat IgG2b Isotype Control Purified

11-169-C100 0.1 mg
EUR 136

Rat IgG2b Isotype Control FITC

1F-169-C025 0.025 mg
EUR 108

Rat IgG2b Isotype Control FITC

1F-169-C100 0.1 mg
EUR 177

Rat IgG2b Isotype Control (APC)

abx405049-100tests 100 tests
EUR 425

Rat IgG2b Isotype Control (Biotin)

abx405050-01mg 0.1 mg
EUR 314

Rat IgG2b Isotype Control (FITC)

abx405052-01mg 0.1 mg
EUR 342

Rat IgG2b Isotype Control (RPE)

abx405055-100tests 100 tests
EUR 356

Mouse IgG2b Isotype Control

abx139006-01mg 0.1 mg
EUR 314

Mouse IgG2b Isotype Control

abx139011-01mg 0.1 mg
EUR 314

Mouse IgG2b Isotype Control

abx405056-100tests 100 tests
EUR 411

Mouse IgG2b Isotype Control

abx405061-1mg 1 mg
EUR 1080

Mouse IgG2b Isotype Control

abx200580-100ug 100 ug
EUR 314

Rat IgG2b-Biotin conjugate (isotype control)

20005-13-B 100 ug
EUR 202

Rat IgG2b-FITC conjugate (isotype control)

20005-13-F 100 ug
EUR 225

Rat IgG2b-HRP conjugate (isotype control)

20005-13-HP 100 ug
EUR 202

Rat IgG2b Isotype Control LOW ENDOTOXIN

12-169-C100 0.1 mg
EUR 136

Rat IgG2b Isotype Control (Pacific Blue)

abx405054-100tests 100 tests
EUR 384

Mouse IgG2b Isotype Control PerCP

PC-692-C025 0.025 mg
EUR 122

Mouse IgG2b Isotype Control PerCP

PC-692-C100 0.1 mg
EUR 204

Mouse IgG2b isotype control, purified

20102-103 100 ug
EUR 141

Mouse IgG2b Isotype Control Purified

11-692-C025 0.025 mg
EUR 88

Mouse IgG2b Isotype Control Purified

11-692-C100 0.1 mg
EUR 136

Mouse IgG2b Isotype Control Purified

11-801-C025 0.025 mg
EUR 88

Mouse IgG2b Isotype Control Purified

11-801-C100 0.1 mg
EUR 136

Mouse IgG2b Isotype Control APC

1A-692-C025 0.025 mg
EUR 122

Mouse IgG2b Isotype Control APC

1A-692-C100 0.1 mg
EUR 204

Mouse IgG2b Isotype Control Biotin

1B-692-C025 0.025 mg
EUR 108

Mouse IgG2b Isotype Control Biotin

1B-692-C100 0.1 mg
EUR 177

Mouse IgG2b Isotype Control FITC

1F-692-C025 0.025 mg
EUR 108

Mouse IgG2b Isotype Control FITC

1F-692-C100 0.1 mg
EUR 177

Mouse IgG2b Isotype Control PE

1P-692-C025 0.025 mg
EUR 122

Mouse IgG2b Isotype Control PE

1P-692-C100 0.1 mg
EUR 204

Mouse IgG2b Isotype Control (Biotin)

abx139018-01mg 0.1 mg
EUR 384

Mouse IgG2b Isotype Control (PE)

abx139020-01mg 0.1 mg
EUR 425

Mouse IgG2b Isotype Control (APC)

abx139017-01mg 0.1 mg
EUR 425

Mouse IgG2b Isotype Control (FITC)

abx139019-01mg 0.1 mg
EUR 384

Mouse IgG2b Isotype Control (PerCP)

abx139021-01mg 0.1 mg
EUR 425

Mouse IgG2b Isotype Control (APC)

abx405057-100tests 100 tests
EUR 481

Mouse IgG2b Isotype Control (Biotin)

abx405058-100tests 100 tests
EUR 411

Mouse IgG2b Isotype Control (FITC)

abx405059-100tests 100 tests
EUR 411

Mouse IgG2b Isotype Control (RPE)

abx405060-100tests 100 tests
EUR 467

Mouse IgG2b Isotype Control (FITC)

abx200581-100ug 100 ug
EUR 314

Mouse IgG2b Isotype Control (PE)

abx200582-50ug 50 ug
EUR 425

Mouse IgG2b Isotype Control (APC)

abx200583-50ug 50 ug
EUR 425

Mouse IgG2b Isotype Control (PerCP)

abx200584-100ug 100 ug
EUR 425

Mouse IgG2b Isotype control; Concentrate

NG907C 1 ml
EUR 357

Mouse IgG2b-FITC (isotype control)

MG2bF-100 100 Tests
EUR 408

Rat IgG2b-R-PE conjugate (isotype control)

20005-13-PE 25 tests
EUR 202

Mouse IgG2b Isotype Control PE-Cy5

T8-692-C025 0.025 mg
EUR 136

Mouse IgG2b Isotype Control PE-Cy5

T8-692-C100 0.1 mg
EUR 231

Mouse IgG2b Isotype Control PerCP-Cy5.5

T9-692-C025 0.025 mg
EUR 170

Mouse IgG2b Isotype Control PerCP-Cy5.5

T9-692-C100 0.1 mg
EUR 300

Mouse IgG2b-Biotin conjugate (isotype control)

20102-103-B 50 Tests
EUR 164

Mouse IgG2b-FITC conjugate (isotype control)

20102-103-F 50 tests
EUR 164

Mouse IgG2b-HRP conjugate (isotype control)

20102-103-HP 50 Tests
EUR 164

Mouse IgG2b-PE conjugate (isotype control)

20102-103-PE 50 Tests
EUR 164

Mouse IgG2b Isotype Control (CF-Blue)

abx200585-100ug 100 ug
EUR 425

Mouse IgG2b Isotype Control (OC-515)

abx200586-100ug 100 ug
EUR 481

IgG2b Isotype Control Fc fusion protein

35R-0025 100 ug
EUR 165
Description: Rat monoclonal IgG2b Isotype Control Fc fusion protein

IgG2b Isotype Control Fc fusion protein

35R-0031 100 ug
EUR 181
Description: Mouse monoclonal IgG2b Isotype Control Fc fusion protein

IgG2b Kappa Isotype Control antibody (Biotin)

61R-2065 500 ug
EUR 284
Description: Mouse monoclonal IgG2b Kappa Isotype Control antibody (Biotin)

Rat IgG2b-R-PE-Cy5.5 conjugate (isotype control)

20005-13-PC5 25 tests
EUR 213

Rat IgG2b Isotype Control (LTF-2), Untagged-100ug

QAB62-100ug 100ug
EUR 131

Rat IgG2b Isotype Control (LTF-2), APC-100ug

QAB62-APC-100ug 100ug
EUR 208

Rat IgG2b Isotype Control (LTF-2), FITC-100ug

QAB62-F-100ug 100ug
EUR 182

Rat IgG2b Isotype Control (LTF-2), PE-100ug

QAB62-PE-100ug 100ug
EUR 182

Rat IgG2b Isotype Control (LTF-2), V450-100ug

QAB62-V450-100ug 100ug
EUR 200

Mouse IgG2b-PE-Cy5 conjugate (isotype control)

20102-103-PC5 50 Tests
EUR 225

Mouse IgG2b Isotype Control, FITC Conjugated mAb

28279-50Tests 50 Tests
EUR 252

Mouse IgG2b Isotype Control, PE Conjugated mAb

28280-50Tests 50 Tests
EUR 252

Mouse IgG2b Isotype control; Ready-To-Use

NG907 7 ml
EUR 334

IgG2b Isotype Control Fc fusion protein (FITC)

35R-0006 100 ug
EUR 235
Description: Rat monoclonal IgG2b Isotype Control Fc fusion protein (FITC)

IgG2b Isotype Control Fc fusion protein (FITC)

35R-0012 100 ug
EUR 235
Description: Mouse monoclonal IgG2b Isotype Control Fc fusion protein (FITC)

IgG2b Isotype Control Fc fusion protein (PE)

35R-0014 100 ug
EUR 278
Description: Rat monoclonal IgG2b Isotype Control Fc fusion protein (PE)

IgG2b Isotype Control Fc fusion protein (PE)

35R-0020 100 ug
EUR 278
Description: Mouse monoclonal IgG2b Isotype Control Fc fusion protein (PE)

IgG2b Isotype Control Fc fusion protein (biotin)

35R-0021 100 ug
EUR 208
Description: Rat monoclonal IgG2b Isotype Control Fc fusion protein (biotin)

IgG2b Isotype Control Fc fusion protein (allophycocyanin)

35R-0032 100 ug
EUR 386
Description: Rat monoclonal IgG2b Isotype Control Fc fusion protein (allophycocyanin)

IgG2b Isotype Control Fc fusion protein (allophycocyanin)

35R-0038 50 ug
EUR 208
Description: Mouse monoclonal IgG2b Isotype Control Fc fusion protein (allophycocyanin)

Rat IgG2b Isotype Control (LTF-2), APC-Cy7-100ug

QAB62-APC7-100ug 100ug
EUR 200

Rat IgG2b Isotype Control (LTF-2), PerCP-Cy5.5-100ug

QAB62-PCP55-100ug 100ug
EUR 200

Rat IgG2b Isotype Control (LTF-2), PE-Cy5-100ug

QAB62-PE5-100ug 100ug
EUR 208

Rat IgG2b Isotype Control (LTF-2), PE-Cy7-100ug

QAB62-PE7-100ug 100ug
EUR 200

Rat IgG2b Isotype Control (LTF-2), QFluor-710-100ug

QAB62-QF710-100ug 100ug
EUR 200

IgG2b isotype control Monoclonal Antibody [MPC11], FITC Conjugated

A24006 50 µg Ask for price
Description: fast delivery possible

IgG2b isotype control Monoclonal Antibody [MPC11], PE Conjugated

A24007 200 µg Ask for price
Description: The best epigenetics products

Mouse IgG2b Isotype Control (MPC-11), Untagged-100ug

QAB67-100ug 100ug
EUR 141

Mouse IgG2b Isotype Control (MPC-11), APC-100ug

QAB67-APC-100ug 100ug
EUR 191

Mouse IgG2b Isotype Control (MPC-11), FITC-100ug

QAB67-F-100ug 100ug
EUR 149

Mouse IgG2b Isotype Control (MPC-11), PE-100ug

QAB67-PE-100ug 100ug
EUR 216

Mouse IgG2b Isotype Control (MPC-11), V450-100ug

QAB67-V450-100ug 100ug
EUR 216

Rat IgG-Biotin conjugate (isotype control) (Isotype control)

20005-B 100 ug
EUR 164

Rat IgG-FITC conjugate (isotype control) (Isotype control)

20005-F 100 ug
EUR 164

Rat IgG-HRP conjugate (isotype control) (Isotype control)

20005-HP 100 ug
EUR 164

Rat IgG-PE conjugate (isotype control) (Isotype control)

20005-PE 25 tests
EUR 202

Mouse IgG2b Isotype Control DyLight® 488

L4-692-C100 0.1 mg
EUR 213

Mouse IgG2b Isotype Control DyLight® 650

L6-692-C100 0.1 mg
EUR 213

IgG2b isotype control Monoclonal Antibody [MPC11], DyLight 488 Conjugated

A24005 200 µg Ask for price
Description: Ask the seller for details

Mouse IgG2b Isotype Control (MPC-11), APC-Cy7-100ug

QAB67-APC7-100ug 100ug
EUR 251

Mouse IgG2b Isotype Control (MPC-11), PerCP-Cy5.5-100ug

QAB67-PCP55-100ug 100ug
EUR 233

Mouse IgG2b Isotype Control (MPC-11), PE-Cy7-100ug

QAB67-PE7-100ug 100ug
EUR 233

Mouse IgG2b Isotype Control (MPC-11), QFluor-710-100ug

QAB67-QF710-100ug 100ug
EUR 216

Rat IgG2a Isotype Control

11-168-C025 0.025 mg
EUR 87

Rat IgG1 Isotype Control

abx405020-05mg 0.5 mg
EUR 384

Rat IgG2a Isotype Control

abx405022-1ml 1 ml
EUR 300

Rat IgG2a Isotype Control

abx405024-05mg 0.5 mg
EUR 384

Rat IgG2a Isotype Control

abx405027-1mg 1 mg
EUR 565

Rat IgG2c Isotype Control

abx405034-025mg 0.25 mg
EUR 537

Rat IgG1 Isotype Control

abx405039-05mg 0.5 mg
EUR 384

Rat IgG1 Isotype Control

20-abx405041
  • EUR 300.00
  • EUR 439.00
  • 0.1 mg
  • 1 mg

Rat IgG2a Isotype Control

abx405045-05mg 0.5 mg
EUR 384

Rat IgG2a Isotype Control

20-abx405047
  • EUR 300.00
  • EUR 439.00
  • 0.1 mg
  • 1 mg

Rat IgG2a Isotype Control

abx200644-500ug 500 ug
EUR 481

Rat IgG1 Isotype Control

RIGG1A-100 100 µg
EUR 545.04

In this research, L-his and L-glu had been used to change the structural properties of HA in numerous experimental situations and buffer techniques (tris and hepes). The outcomes confirmed that L-his was in a position to regulate the plate-shaped morphology of HA in each experimental situation, in contrast to the L-glu, the place the crystal morphology was regulated by experimental situations. Both amino acids behaved in another way in DI water, tris, and hepes buffer, and the media used influenced the precipitation time and structural properties of HA.

Hepes and tris buffers additionally influenced the HA precipitation course of. Overall, the research revealed that L-his could also be used as an efficient regulator of plate-shaped morphology of HA, as a substitute of massive NCPs/proteins, for designing biomaterials for bone regeneration functions and the selection of buffer system is vital in designing and evaluating the techniques for mineralization. In cell tradition research, mouse osteoblast precursor cells (MC3T3-E1) confirmed highest proliferation on the bone-like plate-shaped HA, amongst all of the HA samples investigated.


In vivo biocompatibility and biodegradability of poly(lactic acid)/poly(ε-caprolactone) blend compatibilized with poly(ε-caprolactone- b-tetrahydrofuran) in Wistar rats

In vivo biocompatibility and biodegradability of poly(lactic acid)/poly(ε-caprolactone) blend compatibilized with poly(ε-caprolactone- b-tetrahydrofuran) in Wistar rats

Poly(lactic acid) (PLA) and poly(ɛ-caprolactone) (PCL) are two necessary aliphatic esters identified for his or her biodegradability and bioresorbability properties; the previous is stiffer and brittle whereas the smaller modulus of the latter permits an appropriate elongation. The new biomaterials being developed from the blend of these two polymers (PLA and PCL) is opportune because of the decreasing interfacial stress between their immiscible phases. In a earlier research, PLA/PCL immiscible blend when compatibilized with poly(ε-caprolactone-b-tetrahydrofuran) resulted in enhanced ductility and toughness no cytotoxic impact in vitro exams. There is little printed knowledge on the impact of poly(ε-caprolactone-b-tetrahydrofuran) on PLA and PCL biocompatibility and biodegradability in vivo exams.

This research focuses on evaluating the behavioral response and polymer-tissue interplay of compatibilized PLA/PCL blend in comparison with neat PLA implanted by way of intraperitoneal (IP) and subcutaneous (SC) in male Wistar rats, distributed in 4 experimental teams: neat PLA, PLA/PCL blend, sham, and management at 2-, 8- and 24-weeks post-implantation (WPI). Open-field take a look at was carried out to appraise emotionality and spontaneous locomotor exercise. Histopathological investigation utilizing hematoxylin-eosin (H&E) and picrosirius-hematoxylin (PSH) was used to evaluate polymer-tissue interplay. Modifications in PLA and the PLA / PCL blend’s floor morphology have been decided by scanning electron microscopy (SEM).

PLA group defecated extra typically than PLA/PCL rats 2 and Eight WPI. Conjunctive capsule growth round implants, cell adhesion, angiogenesis, and big cells of a international physique to the biomaterial was noticed in gentle microscopy. Both teams displayed a fibrous response alongside with collagen deposition across the biomaterials. In the SEM, the photographs confirmed a better degradation price for the PLA/PCL blend in each implantation routes. The polymers implanted by way of IP exhibited a better degradation price in comparison with SC. These findings emphasize the biocompatibility of the PLA/PCL blend compatibilized with poly(ε-caprolactone-b-tetrahydrofuran), making this biopolymer an appropriate different in a range of biomedical applicatio.

Design issues for engineering 3D fashions to check vascular pathologies in vitro

Many cardiovascular ailments (CVD) are pushed by pathological remodelling of blood vessels, which might result in aneurysms, myocardial infarction, ischaemia and strokes. Aberrant remodelling is pushed by adjustments in vascular cell behaviours mixed with degradation, modification, or irregular deposition of extracellular matrix (ECM) proteins. The underlying mechanisms that drive the pathological remodelling of blood vessels are multifaceted and illness particular; nevertheless, unravelling them could also be key to growing therapies. Reductionist fashions of blood vessels created in vitro that mix cells with biomaterial scaffolds could function helpful analogues to check vascular illness development in a managed setting.
This evaluate presents the primary issues for growing such in vitro fashions. We talk about how the design of blood vessel fashions impacts experimental readouts, with a specific give attention to the upkeep of regular mobile phenotypes, methods that mimic regular cell-ECM interactions, and approaches that foster intercellular communication between vascular cell varieties. We additionally spotlight how selection of biomaterials, mobile preparations and the inclusion of mechanical stimulation utilizing fluidic gadgets collectively impression the flexibility of blood vessel fashions to imitate in vivo circumstances. In the longer term, by combining advances in supplies science, cell biology, fluidics and modelling, it might be attainable to create blood vessel fashions which are patient-specific and can be utilized to develop and take a look at therapies.
In vivo biocompatibility and biodegradability of poly(lactic acid)/poly(ε-caprolactone) blend compatibilized with poly(ε-caprolactone- b-tetrahydrofuran) in Wistar rats

Repair of segmental bone defect utilizing tissue engineered heterogeneous deproteinized bone doped with lithium

Lithium have been proven to play an necessary position in enhancing the osteogenic properties of biomaterials. This research goals to discover the osteogenic enchancment impact of tissue engineered heterogeneous deproteinized bone (HDPB) doped with lithium, and consider their effectiveness in the therapeutic of bone defects. Bone marrow mesenchymal stem cells (BMSCs) have been co-cultured with totally different focus of lithium chloride. Cell proliferation in every group was analyzed by 3-(4, 5-dimetyl-2-thiazoly-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay.

BMSCs have been then co-cultured in osteogenic induction medium with totally different focus of lithium chloride, and the expression of associated mRNA was detected. The position of lithium in selling BMSCs osteogenic differentiation and inhibiting BMSCs lipogenic differentiation was additionally investigated. Biomechanical properties of the tibia have been evaluated at Eight weeks after operation. The tibial specimens of every group have been collected at 4 and Eight weeks after surgical procedure for histological examination and histological evaluation.

Micro-computed tomography (CT) scanning and 3D reconstruction have been carried out at Eight weeks. The outcomes display that lithium can induce the osteogenic differentiation inhibit of adipogenic differentiation of BMSCs by regulating the Wnt signaling pathway. The histological analysis additional licensed that common bone formation space in the group of tissue engineered HDPB doped with lithium was additionally considerably higher than that of HDPB alone group. Based on the above analysis, tissue engineered HDPB doped with lithium can successfully promote the regeneration of segmental bone defect, which can be utilized as a tissue engineering scaffold for medical trials.

GFP Expressing Human Gastric Carcinoma N87 Cells

TR02-GFP 500,000 Cells
EUR 1354

GFP Expressing Human Renal Adenocarcinoma Cells (ACHN)

TR04-GFP 500,000 Cells
EUR 1354

GFP Expressing Human Prostate Carcinoma Cells (DU 145)

TR03-GFP 500,000 Cells
EUR 1354

CD14-Rluc (GFP) Lentivirus 

LVP1000-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express Renilla luciferase reporter under the human CD14 promoter which demonstrates strongly upregulated expression during monocytic cell differentiation. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-GFP (Bsd) Lentivirus 

LVP1001-B 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets.. This lentivirus also contain the Blasticidin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-GFP (Neo) Lentivirus 

LVP1001-N 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets.. This lentivirus also contain the Neomycin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-GFP (Puro) Lentivirus 

LVP1001-P 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets. This lentivirus also contain the puromycin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-GFP (RFP) Lentivirus 

LVP1001-R 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets. This lentivirus also contain the RFP selection marker under the constitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-RFP (GFP) Lentivirus 

LVP1002-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express RFP reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets.. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-Luc (GFP) Lentivirus 

LVP1003-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express Firefly luciferase reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets.. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD43-Rluc (GFP) Lentivirus 

LVP1004-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express Renilla luciferase reporter under the human CD43 promoter which expressed on the surface of leukocytes and platelets.. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-GFP (Bsd) Lentivirus 

LVP1005-B 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the Blasticidin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-GFP (Neo) Lentivirus 

LVP1005-N 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the Neomycin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-GFP (Puro) Lentivirus 

LVP1005-P 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the puromycin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-GFP (RFP) Lentivirus 

LVP1005-R 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the RFP selection marker under the constitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-RFP (GFP) Lentivirus 

LVP1006-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express RFP reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-Luc (GFP) Lentivirus 

LVP1007-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express Firefly luciferase reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the GFP selection marker under the consitutiveRSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD45-Rluc (GFP) Lentivirus 

LVP1008-G 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express Renilla luciferase reporter under the human CD45's promoter which expressed exclusively by all hematopoietic cells except erythrocytes and platelets. This lentivirus also contain the GFP selection marker under the consitutive RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD68-GFP (Bsd) Lentivirus 

LVP1009-B 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD68's promoter which expressed specifically in macrophages and macrophage-related cells. This lentivirus also contain the Blasticidin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD68-GFP (Neo) Lentivirus 

LVP1009-N 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD68's promoter which expressed specifically in macrophages and macrophage-related cells. This lentivirus also contain the Neomycin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD68-GFP (Puro) Lentivirus 

LVP1009-P 1x107 IFU/ml x 200ul
EUR 552
Description: Pre-made lentivirus express GFP reporter under the human CD68's promoter which expressed specifically in macrophages and macrophage-related cells. This lentivirus also contain the puromycin selection marker under RSV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.

CD68-GFP (RFP) Lentivirus 

LVP1009-R